



## Patent

Docket Number: PUR-00114.P.1.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 08 2002

TEST CENTER 1000/300


Assistant Commissioner for Patents  
Washington D.C. 20231

Sir:

**STATEMENT UNDER 37 C.F.R. 1.821 - 1.825**

In accordance with the requirements under 37 C.F.R. 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, Applicants submit herewith a Substitute Sequence Listing and corresponding Computer-Readable Sequence Listing for the above-identified application. The contents of the enclosed Substitute Sequence Listing and Computer-Readable Sequence Listing are identical. Support for the sequence in the Substitute Sequence Listing can be found in the Sequence Listing as filed with the above-identified application on April 11, 2001. No substantive changes to the Sequence Listing have been made. Thus, the substitute Sequence Listing and Computer-Readable Sequence Listing include no new matter.

Respectfully submitted,



David R. Preston

Reg. No. 38,710

Date: Feb 8, 2002

David R. Preston & Associates

12625 High Bluff Drive

Suite 205

San Diego, CA 92130

858.724.0375



Patent

Docket Number: PUR-00114.P.1.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: )  
Judy Raucy ) Examiner: To be determined  
Application No.: 09/832,621 ) Art Unit: To be determined  
Filed: April 11, 2001 )  
For: COMPOSITIONS AND )  
METHODS FOR INDUCTION OF )  
PROTEINS INVOLVED IN )  
XENOBIOTIC METABOLISM )

RECEIVED

MAY 08 2002

TECH CENTER 1600/300


Assistant Commissioner for Patents  
Washington D.C. 20231

Sir:

LETTER TO THE COMMISSIONER UNDER 37 C.F.R. 1.821 - 1.825

In accordance with the requirements of 37 C.F.R. 1.821 - 1.825, Applicants submit herewith a substitute Sequence Listing in accordance with 37 C.F.R. 1.825(a), a Sequence Listing in computer-readable form in accordance with 37 C.F.R. 1.825(b) and a statement under 37 C.F.R. 1.825(a) - (b) that the substitute Sequence Listing and its corresponding computer-readable form are identical, that provides support for the substitute Sequence Listing and that both the substitute Sequence Listing and its corresponding computer-readable form include no new matter. Thus, Applicants have fully met the requirements of 37 C.F.R. 1.821 - 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. This submission is being made within one month or thirty days from October 10, 2001, the mailing date of the Office Communication. Thus no extensions of time are deemed necessary.

Respectfully submitted,



Date: October 17, 2001

David R. Preston

Reg. No. 38,710

David R. Preston & Associates  
12625 High Bluff Drive  
Suite 205  
San Diego, CA 92130  
858.724.0375